

IN THE CLAIMS:

Please amend the claims as follows:

1. - 20. (Cancelled)

21. (Currently Amended) A purified or isolated antibody or a functional fragment thereof comprising a heavy chain variable region with at least 80% identity to ~~the amino acid sequence of SEQ ID NO:5 and that includes amino acids 99-108 of SEQ ID NO:5~~, and a light chain variable region with at least 80% identity to the amino acid sequence of SEQ ID NO:7, and wherein the antibody or functional fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSM ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells ~~an adenocarcinoma of the colon, a diffuse type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung.~~

22. (Previously Presented) The purified or isolated antibody or a functional fragment thereof of claim 21, wherein said antibody or a functional fragment thereof comprises a heavy chain variable region with at least 85% identity to the amino acid sequence of SEQ ID NO:5.

23. (Previously Presented) The purified or isolated antibody or a functional fragment thereof of claim 22, wherein said antibody or a functional fragment thereof comprises a light chain variable region with at least 85% identity to the amino acid sequence of SEQ ID NO:7.

24. - 26. (Cancelled)

27. (Currently Amended) A purified or isolated antibody or a functional fragment thereof comprising amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 or amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7, wherein the antibody or functional fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699

(DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSM ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells.

28. (Previously Presented) The purified or isolated antibody or functional fragment of claim 27, wherein said antibody or functional fragment thereof comprises amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5.

29. (Currently Amended) The purified or isolated antibody or functional fragment of claim 27, wherein said antibody or functional fragment comprises amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7, ~~and specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung.~~

30. (Currently Amended) The purified or isolated-antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment thereof specifically binds to Colo-699 (DSMZ Accession Number ACC 196), ~~CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201),~~ DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

31. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or 27, wherein said antibody is a monoclonal antibody or a functional fragment thereof.

32. (Currently Amended) The purified or isolated functional fragment of claim 21 or 27, wherein said functional fragment is selected from the group consisting of V_L, V_H, F_v, [[F_c,]] Fab, Fab', and F(ab')₂.

33.-34. (Cancelled)

35. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or 27, comprising amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 and amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7.

36. - 46. (Cancelled)

47. (Currently Amended) The purified or isolated antibody or functional fragment of claims, 21 or 27 wherein said polypeptide antibody is produced by the NORM-2 cell line having DSMZ deposit accession number DSM ACC2626.

48. - 88. (Cancelled)

89. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a heavy chain variable region at least 90% identical to SEQ ID NO:5.

90. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a light chain variable region at least 90% identical to SEQ ID NO:7.

91. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a heavy chain variable region at least 95% identical to SEQ ID NO:5.

92. (Previously Presented) The purified or isolated antibody or functional fragment of any one of claim 21 or claim 27, wherein said antibody or functional fragment comprises a light chain variable region at least 95% identical to SEQ ID NO:7.

93. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein said antibody or functional fragment induces apoptosis of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

94. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein said antibody or functional fragment decreases proliferation of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number

ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.

95. (Previously Presented) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein the heavy or light chain variable region has an insertion, deletion or substitution of one amino acid residue.

96. (Currently Amended) A purified or isolated antibody or a functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:5 and SEQ ID NO:7 with one amino acid insertion, deletion or substitution in either or both of SEQ ID NO:5 and SEQ ID NO:7, wherein the antibody or functional fragment thereof specifically binds to an epitope of an antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells, wherein NORM-2 antibody produced by a cell line deposited as DSM ACC 2626 specifically binds to said epitope of the antigen expressed by at least one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), and BM 1604 (DSMZ Accession Number ACC 298) cells.